284 results
Page 7 of 15
S-3ASR
akha307enqp4d7np 0e
11 Dec 18
Automatic shelf registration
4:40pm
8-K
EX-99.1
bhpib
10 Dec 18
Completion of Acquisition or Disposition of Assets
5:14pm
8-K
EX-99.2
y0vluxlf78nhl
10 Dec 18
Completion of Acquisition or Disposition of Assets
5:14pm
8-K
EX-99.1
v3zrfo
7 Nov 18
Regulation FD Disclosure
5:22pm
8-K
EX-99.1
26bn 7b7de68p
30 Oct 18
NeoGenomics Reports 17% Revenue Growth to Record $69 Million
8:12am
8-K
EX-2.1
y3bewp4llrbzo
26 Oct 18
Entry into a Material Definitive Agreement
5:23pm
8-K
EX-99.2
disx7tq 2vp7g1j
23 Oct 18
NeoGenomics Signs Definitive Agreement to Acquire Genoptix
5:24pm
8-K
EX-1.1
7khsh m1rc75v3
10 Aug 18
NeoGenomics Announces Pricing on Public Offering of Common Stock
10:29am
424B5
xoqg3nkz46g16bapgkvq
10 Aug 18
Prospectus supplement for primary offering
10:09am
424B5
rzcc9xb1klhhn8 ur72
6 Aug 18
Prospectus supplement for primary offering
4:59pm
8-K
EX-99.2
yivk5rrf87s8k1aot
6 Aug 18
NeoGenomics Announces Proposed Public Offering of Common Stock
4:42pm
8-K
EX-99.1
wjopd 9n81zyg4c29j
24 Jul 18
NeoGenomics Reports Record Revenue of $67.7 Million with 14% Increase in Clinical Volume Growth and 95% Increase in Pharma Services Backlog
8:11am
8-K
EX-99.1
ze9ua kwet83
25 May 18
Regulation FD Disclosure
5:11pm
8-K
EX-99.1
9lfk25eo99n3qcleo2b
25 May 18
Regulation FD Disclosure
5:06pm
8-K
EX-99.1
uidqaegf nmn
1 May 18
NeoGenomics Reports Revenue of $63.4 Million, Net Income of $0.6 Million and Adjusted EBITDA of $9.2 Million in the First Quarter of 2018
7:52am